AVIR · Atea Pharmaceuticals, Inc.
$5.00
+0.25 (+5.26%)
At close · Aug 6
Market Cap
$399.34M
Shares
80.03M
Atea Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for Atea Pharmaceuticals, Inc. (AVIR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY26 · Q1
2026-05-12
Atea Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone
Phase 3 HCV pivotal trials
Hepatitis E (HEV) program / AT587
Regulatory engagement
Diluted EPS
$-0.57
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Atea Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone
Commercial launch preparation
Hepatitis C market opportunity
Phase 3 HCV program execution
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Atea Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone
Bemifovir and riluzole regimen differentiation
Phase III CBEYOND and C FORWARD trials
Phase II SVR12 history and predictability
Diluted EPS
$-0.53
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Atea Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone
Unmet Need and Market Opportunity
HCV Phase III Program Progress
Market Research / Prescriber Preference
Diluted EPS
$-0.44
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-14
Atea Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone
Phase 3 trial design and initiation
HCV market opportunity and unmet need
Phase 2 results and HCV cure rate
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Atea Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Positive tone
HCV Phase III readiness
HCV unmet need and patient profile
FDA end of Phase II meeting
Diluted EPS
$-0.37
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Atea Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone
COVID-19 program (bemnifosbuvir / SUNRISE-3)
HCV combination program (bemnifosbuvir + ruzasvir)
Phase 2 HCV leading cohort results (EASL)
Diluted EPS
$-0.48
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Atea Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone
HCV Phase II / Phase III program
Fixed-dose combination tablet development
COVID-19 / bemnifosbuvir program
Diluted EPS
$-0.75
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Atea Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone
HCV Phase 2 combination
COVID-19 / SUNRISE-3 Phase 3
Regulatory pathway / Phase 3 design
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Atea Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.40
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Atea Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.34
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Atea Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.43
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Atea Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Atea Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.10
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Atea Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-0.38
▼ 2000% YoY
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Atea Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-0.51
▼ 250% YoY
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Atea Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Revenue
$192.18M*
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Atea Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$32.81M
Diluted EPS
$-0.34
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Atea Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Revenue
$60.39M
Diluted EPS
$0.02
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Atea Pharmaceuticals, Inc. Q1 FY2021 Earnings Call
Revenue
$65.98M
Diluted EPS
$0.34
Audio
Transcript
Slides
8-K10-Q
Showing 1–20 of 20 earnings calls
Key facts
CIK
1593899
CUSIP
04683R106
13F (30d)
26 filings
26 filers
Visit website
Investor relations